Results 21 to 30 of about 818 (145)

Toxin expression during Staphylococcus aureus infection imprints host immunity to inhibit vaccine efficacy [PDF]

npj Vaccines, 2023
Staphylococcus aureus infections are a major public health issue, and a vaccine is urgently needed. Despite a considerable promise in preclinical models, all vaccines tested thus far have failed to protect humans against S. aureus. Unlike laboratory mice,
Omid Teymournejad, Zhaotao Li, Pavani Beesetty, Ching Yang, Christopher P. Montgomery   +4 more
doaj   +2 more sources

Protection against experimental cryptococcosis elicited by Cationic Adjuvant Formulation 01-adjuvanted subunit vaccines. [PDF]

PLoS Pathogens
The fungal infection, cryptococcosis, is responsible for >100,000 deaths annually. No licensed vaccines are available. We explored the efficacy and immune responses of subunit cryptococcal vaccines adjuvanted with Cationic Adjuvant Formulation 01 (CAF01).
Ruiying Wang, Lorena V N Oliveira, Maureen M Hester, Diana Carlson, Dennis Christensen, Charles A Specht, Stuart M Levitz   +6 more
doaj   +2 more sources

Characterization of the antigen-specific CD4+ T cell response induced by prime-boost strategies with CAF01 and CpG adjuvants administered by the intranasal and subcutaneous routes [PDF]

Frontiers in Immunology, 2015
The design of heterologous prime-boost vaccine combinations that optimally shape the immune response is of critical importance for the development of next generation vaccines.
Annalisa eCiabattini, Gennaro eProta, Dennis eChristensen, Peter eAndersen, Gianni ePozzi, Donata eMedaglini   +5 more
doaj   +2 more sources

Next-generation Candida albicans vaccine VXV-01 containing recombinant Als3p and Hyr1p antigens for invasive Candida infections [PDF]

Scientific Reports
Candida species, including Candida albicans and Candida auris, represent a growing public health concern due to their increasing prevalence and resistance to antifungal agents. C.
Shakti Singh, Eman G. Youssef, Ashley Barbarino, Haley Hautau, Sunna Nabeela, Teclegiorgis Gebremariam, Sondus Alkhazraji, Gary Ostroff, Dennis Christensen, Terrence Cochrane, Ashraf S. Ibrahim   +10 more
doaj   +2 more sources

Liposomal delivery system/adjuvant for tuberculosis vaccine. [PDF]

Immun Inflamm Dis, 2023
The delivery system and safety regulator are common characteristics of effective adjuvants in tuberculosis (TB) vaccines and the clinical trial stage. Based on our findings, the liposomal system is a superb adjuvant for vaccinations against TB, other intracellular infections, and malignancies.
Moradi M, Vahedi F, Abbassioun A, Ramezanpour Shahi A, Sholeh M, Taheri-Anganeh M, Dargahi Z, Ghanavati R, Khatami SH, Movahedpour A.   +9 more
europepmc   +2 more sources

Physiologically Based Pharmacokinetic Modeling of Caffeine in Preterm Neonates: Influence of Renal Function and Impairment on Dosing. [PDF]

J Clin Pharmacol
Abstract Currently, the same weight‐based caffeine citrate dosing regimen is applied to all neonates. However, due to differences in growth trajectories by gestational age (GA) and altered caffeine elimination in neonates with renal injury, optimal dosing regimens may differ. In this study, we refined the existing physiologically based pharmacokinetic (
Thomas N, Harer MW, Lim SY.
europepmc   +2 more sources

H65 fusion protein fails to improve the protection of a rationally attenuated live vaccine candidate against bovine tuberculosis in a mouse model of tuberculosis

International Journal of Mycobacteriology, 2021
Background: The fusion protein H65, composed of Mycobacterium tuberculosis (TB) ESX-secreted antigens, has improved the bacillus Calmette–Guerin-induced immune protection in a mouse model of bovine TB when formulated in the liposomal adjuvant CAF01.
Elizabeth A García, Federico C Blanco, Fabiana Bigi   +2 more
doaj   +1 more source

International consensus statement on allergy and rhinology: Allergic rhinitis – 2023

International Forum of Allergy &Rhinology, Volume 13, Issue 4, Page 293-859, April 2023., 2023
Abstract Background In the 5 years that have passed since the publication of the 2018 International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis (ICAR‐Allergic Rhinitis 2018), the literature has expanded substantially. The ICAR‐Allergic Rhinitis 2023 update presents 144 individual topics on allergic rhinitis (AR), expanded by over 40
Sarah K. Wise, Cecelia Damask, Lauren T. Roland, Charles Ebert, Joshua M. Levy, Sandra Lin, Amber Luong, Kenneth Rodriguez, Ahmad R. Sedaghat, Elina Toskala, Jennifer Villwock, Baharudin Abdullah, Cezmi Akdis, Jeremiah A. Alt, Ignacio J. Ansotegui, Antoine Azar, Fuad Baroody, Michael S. Benninger, Jonathan Bernstein, Christopher Brook, Raewyn Campbell, Thomas Casale, Mohamad R. Chaaban, Fook Tim Chew, Jeffrey Chambliss, Antonella Cianferoni, Adnan Custovic, Elizabeth Mahoney Davis, John M. DelGaudio, Anne K. Ellis, Carrie Flanagan, Wytske J. Fokkens, Christine Franzese, Matthew Greenhawt, Amarbir Gill, Ashleigh Halderman, Jens M. Hohlfeld, Cristoforo Incorvaia, Stephanie A. Joe, Shyam Joshi, Merin Elizabeth Kuruvilla, Jean Kim, Adam M. Klein, Helene J. Krouse, Edward C. Kuan, David Lang, Desiree Larenas‐Linnemann, Adrienne M. Laury, Matt Lechner, Stella E. Lee, Victoria S. Lee, Patricia Loftus, Sonya Marcus, Haidy Marzouk, Jose Mattos, Edward McCoul, Erik Melen, James W. Mims, Joaquim Mullol, Jayakar V. Nayak, John Oppenheimer, Richard R. Orlandi, Katie Phillips, Michael Platt, Murugappan Ramanathan Jr, Mallory Raymond, Chae‐Seo Rhee, Sietze Reitsma, Matthew Ryan, Joaquin Sastre, Rodney J. Schlosser, Theodore A. Schuman, Marcus S. Shaker, Aziz Sheikh, Kristine A. Smith, Michael B. Soyka, Masayoshi Takashima, Monica Tang, Pongsakorn Tantilipikorn, Malcolm B. Taw, Jody Tversky, Matthew A. Tyler, Maria C. Veling, Dana Wallace, De Yun Wang, Andrew White, Luo Zhang, Omar G. Ahmed, Khashayar Arianpour, Emily Barrow, Carlo Cavaliere, Juan Carlos Ceballos Cantu, Mark B. Chaskes, Andy Jian Kai Chua, Srihari Daggumati, Luke Daines, Paul Daraei, Thomas Edwards, Deanna Gigliotti, Mitchell Gore, Khodayar Goshtasbi, Doo Hee Han, Lubnaa Hossenbaccus, Megan Jolicoeur, Dichapong Kanjanawasee, Suat Kilic, Sophia Linton, David Liu, Christoper Low, Chengetai Mahomva, Jordan A. Malenke, Amar Miglani, Peter Nagy, Jin‐A Park, Marianella Paz‐Lansberg, Paul Pfeffer, Marisa Ryan, Anirudh Saraswathula, Cameron Sheehan, Nadja Struss, Kevin Tie, Sina Torabi, Esmond F. Tsai, Nathalia Velasquez, Jackson Vuncannon, Duncan Watley, Xinni Xu   +126 more
wiley   +1 more source

Key Considerations for the Development of Safe and Effective SARS‐CoV‐2 Subunit Vaccine: A Peptide‐Based Vaccine Alternative

Advanced Science, Volume 8, Issue 16, August 18, 2021., 2021
Careful antigen selection is essential for development of an effective and safe SARS‐CoV‐2 vaccine. Considering recent advances, peptide vaccines can be ideal substitutes for protein and RNA/DNA‐based vaccines. Peptide vaccines can avoid immunopathological sequences, focus immune responses on neutralizing B‐cell and on T‐cell epitopes, combine antigens
Ahmed O. Shalash, Waleed M. Hussein, Mariusz Skwarczynski, Istvan Toth   +3 more
wiley   +1 more source

Injection Vaccines Formulated with Nucleotide, Liposomal or Mineral Oil Adjuvants Induce Distinct Differences in Immunogenicity in Rainbow Trout

Vaccines, 2020
Protection facilitated by the widespread use of mineral oil adjuvanted injection vaccines in salmonid fish comes with adverse effects of varying severity. In this study, we characterized the immunological profiles of two alternative vaccine formulations,
Kasper Rømer Villumsen, Per Walter Kania, Dennis Christensen, Erling Olaf Koppang, Anders Miki Bojesen   +4 more
doaj   +1 more source